Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Erythropoietin for severe traumatic brain injury
IRCT20230901059316N1Phase 3Completed
- Sponsor
- Mashhad University of Medical Sciences
- Start
- Jan 2024
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised trial of erythropoietin in traumatic brain injury (TBI) (2 arms), sponsored by Mashhad University of Medical Sciences. Primary endpoints: Glasgow Coma Scale and Glasgow Outcome Scale. Started Jan 2024; status: completed.
02
Drugs
erythropoietin
03
Conditions
traumatic brain injury (TBI)
Beyond the preview
Go deeper on IRCT20230901059316N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20230901059316N1.